Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $130.95
    -3.43 (-2.55%)

    Market Cap: $8.55B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Protagonist Therapeutics Inc (PTGX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Protagonist Therapeutics (PTGX) to earn $5.09 per share in the fiscal year ending Dec 31, 2026, on revenue of $566.26M. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.79, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy321.4%
    Buy1178.6%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 90.0% and revenue estimates fall 57.6%.

    Fiscal year ending Dec 31, 2026
    $5.09
    EPS consensus, revenue $566.26M
    Fiscal year ending Dec 31, 2027
    $0.51
    EPS consensus, revenue $240.25M
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$5.09$3.04 to $7.3012$566.26M$420.00M to $674.50M13
    Dec 31, 2027$0.51-$1.17 to $7.6011$240.25M$116.00M to $797.90M13

    Quarterly Estimates

    The EPS consensus rises from -$0.46 for the quarter ending Dec 31, 2026 to $0.36 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.46-$0.83 to $0.6516$22.64M$2.65M to $88.63M15
    Mar 31, 2027$0.36-$0.35 to $1.854$58.33M$16.10M to $191.00M5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202623
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.2% from $4.75.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$5.09$4.77$4.67$4.79$4.75+7.0%
    Fiscal year ending Dec 31, 2027$0.51-$0.10-$0.20-$0.20-$0.14N/A
    Quarter ending Mar 31, 2027$0.36-$0.09-$0.13-$0.13$0.03+1323.8%

    Frequently Asked Questions About PTGX

    What is the PTGX stock forecast?

    Consensus analyst estimates put Protagonist Therapeutics's EPS at $5.09 for the fiscal year ending Dec 31, 2026, on revenue of $566.26M. The consensus rating from 14 analysts is Buy.

    How do analysts rate PTGX stock?

    Of 14 analysts covering Protagonist Therapeutics, 3 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PTGX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.09, with estimates from $3.04 to $7.30 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.51, with estimates from -$1.17 to $7.60 from 11 analysts.

    What revenue do analysts expect from Protagonist Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $566.26M, with estimates from $420.00M to $674.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $240.25M, with estimates from $116.00M to $797.90M.

    How many analysts cover PTGX?

    14 analysts rate Protagonist Therapeutics stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.